All In Biotech

NDA 019615 · Baxter Hlthcare

Dopamine Hydrochloride In Dextrose 5% In Plastic Container

Dopamine Hydrochloride · Injection

Last checked: Nov 20, 2026Latest source record: Dec 11, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1987

Mar 27, 1987

Approved uses

2

Original approval plus efficacy supplements

Registered trials

586

103 Phase 3, 70 recruiting

FAERS reports

768

730 serious, 321 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 18, 2025.

INDICATIONS AND USAGE Dopamine hydrochloride is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarctions, trauma, endotoxic septicemia, open heart surgery, renal failure and chronic cardiac decompensation as in congestive failure. Where appropriate, restoration of blood volume with a suitable plasma expander or whole blood should be instituted or completed prior to administration of dopamine hydrochloride. Patients most likely to respond adequately to dopamine hydrochloride are those in whom physiological parameters, such as urine flow, myocardial function and blood pressure have not undergone profound deterioration. Reports indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with volume correction and dopamine hydrochloride, the better the prognosis. Poor Perfusion of Vital Organs Urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. Nevertheless, the physician should also observe the patient for signs of reversal of confusion or comatose condition. Loss of pallor, increase in toe temperature and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. Reported studies indicate that when dopamine hydrochloride is administered before urine flow has diminished to levels of approximately 0.3 mL/minute, prognosis is more favorable. Nevertheless, in a number of oliguric or anuric patients, administration of dopamine hydrochloride has resulted in an increase in urine flow which in some cases reached normal levels. Dopamine hydrochloride may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 17, 2001 Supplement 12 · Efficacy LetterReview
  • Mar 27, 1987 Original approval · Type 5 - New Formulation or New Manufacturer
4 products under this application
  • DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER · DOPAMINE HYDROCHLORIDE 320MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER · DOPAMINE HYDROCHLORIDE 80MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER · DOPAMINE HYDROCHLORIDE 640MG/100ML · INJECTABLE, INJECTION · Prescription
  • DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER · DOPAMINE HYDROCHLORIDE 160MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Dopamine" as an intervention, any sponsor and status, largest first.

All 586 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective52
  • hypotension51
  • platelet count decreased46
  • pneumonia46
  • pyrexia44
  • renal impairment42
  • blood pressure decreased38
  • condition aggravated38
  • sepsis37
  • cardiac failure36
  • cardiac arrest35
  • renal failure35

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200454
20059
200612
200722
200838
200932
201042
201145
201239
201338
201428
201538
201640
201725
201831
201937
202026
202148
202248
202332
202437
202530
202614

Recalls

1 FDA enforcement reports for this application.

  • Sep 29, 2014 · Class II · Terminated

    Lack of Assurance of Sterility: A small cut in the solution bag may have been introduced during the manufacturing process, resulting in a leak of the bag into the overpouch.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 3, 2026

    Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03). Demand increase for the drug

  • Current · updated Nov 18, 2026

    Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02).

  • Current · updated Nov 18, 2026

    Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03).

  • Current · updated Nov 18, 2026

    Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,850 on PubMed

Sponsor: Baxter Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.